2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108676
    NF023 hexasodium 104869-31-0 ≥99.0%
    NF023 hexasodium is a selective and competitive P2X1 receptor antagonist, with IC50 values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X1, P2X3, P2X2, and P2X4-mediated responses respectively.
    NF023 hexasodium
  • HY-109157
    Ralmitaront 2133417-13-5 99.92%
    Ralmitaront (RO6889450) is an orally active agonist of trace amine-associated receptor 1 (TAAR1) with a EC50 value of 110.4 nM. Ralmitaront has antipsychotic, cognitively improvement, and antidepressant activity in rodents. Ralmitaront can be used as a neurosuppressant in the study of neuro-related diseases, such as schizophrenia (SCZ), schizoaffective disorder.
    Ralmitaront
  • HY-112173
    Prolylleucine 61596-47-2 99.85%
    Prolylleucine is a dipeptide containing branched-chain amino acids. Prolylleucine can affect the circadian rhythms and behaviour of animals.
    Prolylleucine
  • HY-113410
    3-Methylglutaric acid 626-51-7 ≥98.0%
    3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na+, K+-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na+, K+-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration.
    3-Methylglutaric acid
  • HY-117639
    AUT1 1311136-84-1 99.93%
    AUT1 is a recombinant human Kv3 channel modulator. AUT1 modulates Kv3.1b and Kv3.2a channels in human recombinant with pEC50 values of 5.33 and 5.31 μM, respectively. AUT1 can be used for the research of disorders associated with dysfunction of inhibitory feedback in corticolimbic circuits, such as schizophrenia.
    AUT1
  • HY-119168
    LP-471756 413605-11-5 99.69%
    LP-471756 is a potent GPR139 antagonist with an IC50 value of 640 nM. LP-471756 inhibits LP-360924-stimulated cAMP production.
    LP-471756
  • HY-124151
    Adenosine-2'-monophosphate 130-49-4 ≥98.0%
    Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A2A receptor activation.
    Adenosine-2'-monophosphate
  • HY-128971
    LHVS 170111-28-1
    LHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC50 of 10 μM.
    LHVS
  • HY-129086
    BPAM344 1204572-55-3 99.66%
    BPAM344 is a kainate receptor (KAR) subunits GluK1b, GluK2a, and GluK3a positive allosteric modulator (PAM).
    BPAM344
  • HY-134992
    Vazegepant 1337918-83-8 99.54%
    Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology.
    Vazegepant
  • HY-135108
    QWF Peptide 126088-82-2 98.15%
    QWF Peptide (Compound 4a) is a substance P antagonist with an IC50 of 0.09 μM. QWF Peptide antagonizes the SP-induced contraction of isolated guinea pig trachea strips with an IC50 of 4.7 μM.
    QWF Peptide
  • HY-137499
    NT1-O12B 2739805-63-9
    NT1-O12B, an endogenous chemical and a neurotransmitter-derived lipidoid (NT-lipidoid), is an effective carrier for enhanced brain delivery of several blood-brain barrier (BBB)-impermeable cargos. Doping NT1-O12B into BBB-impermeable lipid nanoparticles (LNPs) gives the LNPs the ability to cross the BBB. NT-lipidoids formulation not only facilitate cargo crossing of the BBB, but also delivery of the cargo into neuronal cells for functional gene silencing or gene recombination.
    NT1-O12B
  • HY-139066
    Punicic acid 544-72-9 ≥98.0%
    Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways.
    Punicic acid
  • HY-146086
    Nrf2 activator-4 2383016-68-8 98.53%
    Nrf2 activator-4 (Compound 20a) is a highly potent, orally active Nrf2 activator with an EC50 of 0.63 µM. Nrf2 activator-4 suppresses reactive oxygen species against oxidative stress in microglia. Nrf2 activator-4 effectively recovers the learning and memory impairment in a scopolamine-induced mouse model.
    Nrf2 activator-4
  • HY-146387
    SIRT5 inhibitor 3 2128651-12-5 ≥98.0%
    SIRT5 inhibitor 3 (compound 46) is a potent and competitive SIRT5 inhibitor with an IC50 value of 5.9 μM. SIRT5 inhibitor 3 can inhibit SIRT5 desuccinylation. SIRT5 inhibitor 3 can be used for researching cancer and neurodegenerative diseases.
    SIRT5 inhibitor 3
  • HY-148772
    PTC258 2476724-74-8 98.72%
    PTC258 is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model.
    PTC258
  • HY-151108
    IDO1/TDO-IN-4 461424-21-5 99.74%
    IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1, and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders.
    IDO1/TDO-IN-4
  • HY-153916
    TCRS-417 2032123-28-5 99.13%
    TCRS-417 (T417) is a small molecule compound capable of docking to the interface between PBX1 and its cognate DNA target sequence, effectively interfering with PBX1-DNA interaction. TCRS-417 can be used in the research of cancer, developmental disorders, inflammatory disorders, autoimmune diseases or neurodegenerative diseases.
    TCRS-417
  • HY-154980
    GPR52 receptor modulator 1 2642079-89-6 99.85%
    GPR52 receptor modulator 1 (Procedure 1) is a GPR52 receptor modulator with the potential to study neuropsychiatric diseases.
    GPR52 receptor modulator 1
  • HY-156650
    Votoplam 2407849-89-0 99.51%
    Votoplam is an HTT gene regulator with an IC50 ≤ 0.1 μM. Votoplam can be used in the research of Huntington's disease.
    Votoplam
Cat. No. Product Name / Synonyms Application Reactivity